AI Science Tracker

IRCCS Regina Elena National Cancer Institute

1 discovery from 2022

Discoveries

Machine-learning-guided screening identifies Bcl-2-family inhibitors IS20 and IS21

Machine-learning-guided virtual screening followed by surface-plasmon-resonance and biological assays identified IS20 and IS21 as compounds binding anti-apoptotic Bcl-2, Bcl-xL and Mcl-1 proteins. Both affected cancer-cell viability and induced apoptosis/autophagic flux in tested cell models; IS21 also reduced tumor growth in leukemia and melanoma mouse models.

Technology: Machine-learning-guided virtual screening (model family not named in PubMed abstract)

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Machine-learning-guided virtual screening followed by surface-plasmon-resonance and biological assays identified IS20 and IS21 as compounds binding anti-apoptotic Bcl-2, Bcl-xL and Mcl-1 proteins.
  • Still unknown: The article calls the compounds potential/new leads; findings are biochemical, cell-based and mouse-model preclinical evidence. It does not establish clinical effectiveness. The PubMed abstract does not specify the machine-learning algorithm, so no specific model architecture is attributed here.
  • AI role: Machine-learning-guided virtual screening prioritized putative Bcl-2-family inhibitor compounds; the candidate hits were then evaluated by surface plasmon resonance and in vitro cell assays, and IS21 was evaluated in mouse tumor models. The reported outcome is the specific assay characterization of IS20 and IS21.

Evidence sources: https://pubmed.ncbi.nlm.nih.gov/35265218/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 48 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.